Kathrin M. Bernt, MD

2016

Haladyna JN, Pastuer T, Riedel SS, Perraud AL, Bernt KM. Transient Potential Receptor Melastatin-2 (TRPM2) Does Not Influence Murine MLL-AF9 Driven AML Leukemogenesis or in Vitro Response to Chemotherapy. Exp Hematol. 2016 Mar 23, PMID: 27033163

Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T* and Bernt KM*. The Histone Methyltransferases MLL and DOT1L cooperate with Meningioma-1 to induce AML. J Clin Invest. 2016 Feb 29. PIMD 26927674

Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna J, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM* and Neff T*. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T-Cell Precursor Acute Lymphoblastic Leukemia. Cell Reports 2016 Mar1; 14(8): 19953-65. PIMD 26904942

2015

Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T. Inactivation of Eed Impedes MLL-AF9 Mediated Leukemogenesis Through Cdkn2a-Dependent and Cdkn2a-Independent Mechanisms in a Murine Model. Exp Hematol. 2015 Nov;43(11):930- 935. PMID:26118502

Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr;21(4):335-43. PMID 25822366

Deshpande AJ, Deshpande AA, Sinha AU, Chen L, Chang J, Zhu N, Koche R, Dzekieva L, Ibanez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder R, Bradner JE, Bernt KM, Armstrong SA. Hox gene expression is controlled by AF10-mediated conversion of H3K79me1 to H3K79me2 in diverse AML subtypes. Cancer Cell 2014 Dec 8;26(6):896-908. PMID: 25464900

Poster Presentations

2016

Wolfe Schneider, K., Wei, Qi, Kuldanek, S., Bernt, KM. Case example involving germline genetic counseling needs for 47,XXX, familial leukemia, and Noonan syndrome following somatic genetic testing. American Society of Pediatric Hematology Oncology (ASPHO) annual meeting, Minneapolis, MN, 2016 – poster presentation.

2015

Simone Riedel, Jessica Haladyna, Matthew Bezzant, Brett Stevens, Daniel A. Pollyea, Amit U. Sinha, Scott Armstong, Qi Wei, Craig T. Jordan, Patricia Ernst, Tobias Neff and Kathrin M. Bernt. Meningeoma-1 cooperates with MLL and DOT1L to induce leukemia. American Society of Hematology (ASH) annual meeting, Orlando, FL, 2015 – poster presentation.

Kathrin M. Bernt. Epigenetics Directing Therapy in Acute Lymphocytic Leukemia: Emerging Roles and New Therapies. American Society of Hematology (ASH) annual meeting, Orlando, FL, 2015 – invited oral presentation.

2014

Simone Riedel, Jessica Haladyna, Matthew Bezzant, Brett Stevens, Daniel A. Pollyea, Craig T. Jordan, Qi Wei, Tobias Neff and Kathrin M. Bernt. Targeting Meningeoma-1 driven AML through epigenetic modulation of the cell of origin. American Society of Hematology (ASH) annual meeting, San Francisco, CA, 2014 – oral presentation.

Jessica N. Haladyna, Taylor L. Yamauchi, Tobias Neff and Kathrin M. Bernt. MDR1 Mediated Drug Resistance to a Histone Methyltansferase Inhibitor (KMT). American Society of Hematology (ASH) annual meeting, San Francisco, CA, 2014 – poster presentation.

Taylor Yamauchi, BA, Kristen Echanique, BS, Jessica Haladyna, BA, Huafeng Xie, Ph.D., Nan Zhu, Ph.D., Simone Riedel, Ph.D., Kathrin M Bernt, MD1, Stuart H. Orkin, MD, Scott A. Armstrong, MD, PhD and Tobias Neff. Context Dependent Role of Polycomb Repressive Complex 2 in Acute Leukemia. American Society of Hematology (ASH) annual meeting, San Francisco, CA, 2014 – oral presentation.

2015

Bernt K. Epigenetics directing therapy in acute lymphocytic leukemia: emerging roles and new therapies. Presented at: ASH Annual meeting: Scientific Program; 2015 Dec 5; Orlando, FL.

Bernt K. How to start a successful laboratory. Presented at: Children’s Hospital Boston/Dana Farber Cancer Institute/Harvard Medical School; 2015 Nov 20; Boston, MA.

Bernt K. Meningioma-1 cooperates with MLL1 and DOT1L to induce leukemia. Presented at: AACR Advances in Pediatric Oncology Meeting; 2015 Nov 10; Fort Lauderdale, FL.

Bernt K. Meningioma-1 driven AML depends on the histone methyltransferase DOT1L. Presented at: Doris Duke Clinical Scientist Meeting; 2015 Apr 23; Chicago, IL.

Bernt K. Targeting Meningeoma-1 driven AML through epigenetic modulation of the cell of origin. Presented at: Keystone Meeting in Hematopoiesis; 2015 Feb 23; Keystone, CO.

2014

Bernt K.  DOT1L inhibition in leukemias with and without MLL-rearrangement. Presented at:  COG (Children’s Oncology Group) Fall Meeting, ALL Biology Session; 2014 Sep 17; Dallas, TX. 

Bernt K.  Histone profiling in cancer using ChIP-Seq and Mass Spec  (together with Ken Figueroa: DNA-methylation profiling, Lucy Godley: DNA hydroxymethylation  profiling). Presented at: AACR annual meeting methods workshop; 2014 Apr 5; San Diego, CA.

2009

Bernt KM, Feigin DR. Interaction of Infection and Nutrition. In: Feigin, Cherry, Demmler, Kaplan: Textbook of Pediatric Infectious Diseases, 5th edition (Feb 2009).

1995

Reutter W, Baum O, Loester K, Fan H, Bork JP, Bernt K, Hanski C, Tauber R. Functional Aspects of the 3 extracellular domains od dipeptidyl peptidase IV (CD26): characterization of glycosylation events, of the collagen binding site and of endopeptidase activity. In: Mol. Biol. Intelligence Units. DPP IV / CD26 in Metabolism and Immune Response. Ed. B. Fleischer, Springer, 1995, pp 55-78.